China has cemented its status as a global innovation powerhouse, fueled largely by an extraordinary expansion of corporate research and development. Yet leading scientists and policy analysts argue that the country’s remarkable growth masks a critical weakness: its business sector invests almost nothing in fundamental science, the very foundation for long-term technological breakthroughs. A recent analysis in Nature underscores the tension between rapid commercialization and the slower, riskier pursuit of basic research, highlighting a pivotal moment for the world’s second-largest economy.
According to the latest data from the Organisation for Economic Co-operation and Development (OECD), China’s companies accounted for roughly 80% of the nation’s US$780 billion R&D expenditure in 2023, adjusted for purchasing power. This is a significant increase from 75% in 2015, reflecting a growing expectation that firms—not just universities and state laboratories—will be the main drivers of scientific advancement. For comparison, corporate R&D in the United States contributed about 70% of total national spending of $820 billion in the same year.
The focus on industry-led research has brought China remarkable gains, particularly in applied sciences and commercially relevant technologies. The country now leads in nearly 90% of crucial technologies that shape economic and strategic interests globally, according to a 2025 report by the Australian Strategic Policy Institute. This represents a dramatic shift from the early 2000s, when China led in just 5% of critical technologies while the United States dominated more than 90%. Industries such as artificial intelligence, quantum computing, and integrated circuits have particularly benefited from this corporate-centric model, with state-backed incentives channeled toward sectors with immediate economic impact.
Despite these achievements, the analysis in Nature warns that China’s long-term innovation trajectory could be constrained by its near-total neglect of fundamental research in the corporate sector. OECD data indicate that in 2023, less than 1% of business R&D in China was devoted to basic sciences, compared with 6% in the United States. Fundamental research, which seeks to uncover underlying principles without immediate commercial applications, has historically yielded the breakthroughs that transform economies, from semiconductors to biotechnology. Without such investments, experts warn, China risks a plateau in its scientific frontier.
Recognizing the gap, analysts suggest that the Chinese government has a golden opportunity to recalibrate incentives. Policies could encourage firms to direct a portion of their R&D budgets toward fundamental projects, while also promoting open-science practices that ensure results undergo peer review and are freely accessible. Open science, as Nature notes, not only strengthens the reliability of research but also benefits society by allowing independent verification and widespread application of discoveries.
There are early signs that the business community is beginning to respond. The OECD highlights a gradual increase in fundamental research conducted by Chinese companies. Notably, in September 2025, China’s DeepSeek-R1 system became the first major large language model to be fully peer-reviewed in a leading academic journal (G. Guo et al. Nature 645, 633; 2025). This milestone underscores both the potential for commercial enterprises to contribute to foundational science and the growing alignment of business R&D with international academic standards.
China’s recent 15th five-year plan, covering 2026–2030, further codifies the role of enterprises as central decision-makers in technological innovation. The plan, summarized by the National People’s Congress, emphasizes that “enterprises [will] implement the principal role … in technological innovation decision-making.” This represents a deliberate delegation of authority from state-led directives to commercial actors, reflecting a belief that businesses are better positioned to translate research into economic growth. Complementing this approach, initiatives such as the Private Enterprise Innovation and Development Joint Fund, launched by the National Natural Science Foundation of China, encourage scientists to link research proposals directly to the innovation needs of participating firms.
Philanthropy is also emerging as a vital source of support for science in China. Wealthy tech entrepreneurs, many with backgrounds in science or R&D-intensive industries, are establishing prizes, grants, and endowments to promote curiosity-driven research. Tencent co-founder Ma Huateng and PDD Holdings founder Colin Huang have followed models similar to U.S. science philanthropists such as Bill Gates and Gordon Moore. Tencent’s Xplorer Prize, for example, awards 50 recipients annually with 3 million yuan ($435,000) each to pursue independent research, while Huang pledged $100 million to Zhejiang University in 2021 to fund fundamental science. These efforts complement state investment, demonstrating a growing recognition within the private sector of the long-term value of basic research.
Yet China’s leadership in applied technologies underscores the stakes involved. Many of the most transformative innovations—ranging from modern computing to advanced materials—have sprung from basic scientific discoveries. By not fully committing to fundamental research, Chinese firms risk creating an innovation ecosystem that excels at commercialization but lacks the underlying scientific engine to sustain global leadership. Experts emphasize that encouraging open, peer-reviewed research in the corporate sector could not only accelerate China’s own progress but also challenge Western companies, which often refrain from publishing proprietary findings, to embrace transparency for the broader benefit of science.
China’s state-led research model has proven remarkably effective at producing immediate technological wins, but Nature’s analysis suggests that the next phase of the country’s scientific journey will require a shift in mindset. If businesses and government together prioritize fundamental research while adhering to international standards of openness and peer review, China could cement its position as not only a leader in commercial innovation but also a pioneer in the global scientific enterprise. The nation’s ability to balance economic incentives with the pursuit of knowledge for its own sake may define its role in the next era of technological competition.
